Latest Desperate parents sold implausible stem cell cures: related news

Latest: Desperate families sold implausible stem-cell therapies

SOME Chinese biotech companies appear to be marketing their services to desperate families, offering implausible and controversial stem cell treatments for childhood blindness and other neurological disorders.

Latest: Desperate parents sold implausible stem-cell 'cures'

Explore our interactive map showing cancer survival rates in different countries. Read the accompanying story

Scientists create 20 disease-specific stem cell lines

(PhysOrg.com) -- Harvard Stem Cell Institute researcher George Q. Daley, associate director of the Stem Cell Program at Children's Hospital Boston, has with HSCI colleagues Chad Cowan and Konrad Hochedlinger of Massachusetts General Hospital produced a robust new collection of disease-specific stem cell lines, all of which were developed using the new induced pluripotent stem cell (iPS) technique. The work is described in a paper published in today's online edition of the journal Cell.

Daley and colleagues create 20 disease-specific stem cell lines

Boston, Mass, Aug. 7, 2008 – Harvard Stem Cell Institute researcher George Q. Daley, MD, PhD, also associate director of the Stem Cell Program at Children's Hospital Boston, and HSCI colleagues Konrad Hochedlinger and Chad Cowan have produced a robust new collection of disease-specific stem cell lines, all of which were developed using the new induced pluripotent stem cell (iPS) technique. The paper is being published in the August 6 on-line edition of the journal Cell.

Desperate parents sold implausible stem-cell 'cures'

Explore our interactive map showing cancer survival rates in different countries. Read the accompanying story

Stem Cell Therapeutics Corp. (Calgary, AB)

Stem Cell Therapeutics Corp. (Calgary, AB) announces that it has been granted U.S. patent no. 7,393,830 entitled “Prolactin induced increase in neural stem cell numbers�, and Australian patent no. 2002325711 entitled “Prolactin induced increase in neural stem cell numbers and therapeutical use thereof�. These patents cover the use of prolactin alone, as well as in combination with other therapeutics. Prolactin is used alone or with anti-inflammatories in programs to treat multiple sclerosis, and in combination with EPO to treat neurodegenerative diseases.

Human Stem Cell Research: Stepping It Up a Notch

Researchers at Johns Hopkins have discovered that the Notch protein helps human embryonic stem cells “decide� their own fate, a finding which may eventually be useful in programming cells for the development of stem cell therapies. Their results are reported in the May 2008 issue of Cell Stem Cell.

Sony Group, Toshiba and IBM Renew Cell Broadband Engine(TM) Center of Competence...

Sony Group, Toshiba and IBM Renew Cell Broadband Engine(TM) Center of Competence with Georgia Tech Upcoming Workshop to Focus on Developing Commercial Applications and Productivity Software for Cell Broadband Engine (Cell/B.E.) Processor ATLANTA--(Business Wire)-- The Georgia Tech College of Computing today announced the renewal of the Sony Corporation/Sony Computer Entertainment Inc. (Sony Group)-Toshiba-IBM Center of Competence (STI Center), based on Georgia Tech's exceptional work in multiple areas of research and evangelism for the Cell Broadband Engine(TM) (Cell/B.E.) technology. Through Georgia Tech's efforts, the STI Center has been responsible for creating and disseminating software optimized for Cell/B.E. systems, and for performing research on the design of Cell/B.

New Stem Cell Screening Tool Takes Adult Stem Cell Research To New Level

Stem cell research is the next great leap in medicine. In the future, new tissue grown in a laboratory could replace a failing heart, or new cells take the place of damaged cells in the brain.

New amaxa Stem Cell Kits Provide Transfection Efficiencies of up to 80%

Amaxa introduces four new Human Stem Cell Nucleofector® Kits, for single reactions and up to 96-well transfections, suitable for various stem cell lines. With these kits, transfection efficiencies of 60% up to 80% can be achieved for stem cells, combined with high viability.

Latest: Consent row threatens stem cell research

It seems that some of the cell lines sanctioned for use by the current US administration may have been obtained without proper consent from the women who provided the original embryos. The ethical storm could halt some federally funded stem cell research.

Lytic Transglycosylase MltB of Escherichia coli and Its Role in Recycling of Peptidoglycan Strands of Bacterial Cell Wall

The cell wall is an indispensable structure for the survival of bacteria and a target for antibiotics. Peptidoglycan is the major constituent of the cell wall, which is comprised of backbone repeats of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM). A peptide stem is appended to the NAM unit, which in turn experiences cross-linking with a peptide from another peptidoglycan in the final steps of cell wall assembly. In the normal course of bacterial growth, as much as 60% of the parental cell wall is recycled, a process that is not fully understood. A polymeric cell wall is fragmented by the family of lytic transglycosylases, and certain key fragments are transported to the cytoplasm for recycling. The genes for the six known lytic transglycosylases of Escherichia coli were cloned, and the enzymes were purified in this study.

Scientists get millions for stem cell research

(08-13) 19:51 PDT -- The governing board of California's stem cell agency awarded a total of $59 million Wednesday to support the budgets of 23 young scientists and physicians throughout the state who have proposed new stem cell research projects.

Sony Group, Toshiba and IBM Renew Cell Broadband Engine(TM) Center of Competence with Georgia Tech

The Georgia Tech College of Computing today announced the renewal of the Sony Corporation/Sony Computer Entertainment Inc. (Sony Group)-Toshiba-IBM Center of Competence (STI Center), based on Georgia Tech's exceptional work in multiple areas of research and evangelism for the Cell Broadband Engine(TM) (Cell/B.E.) technology. Through Georgia Tech's efforts, the STI Center has been responsible for creating and disseminating software optimized for Cell/B.E. systems, and for performing research on the design of Cell/B.E. systems, algorithms and applications. In conjunction with this renewal of the STI Center, Georgia Tech is announcing a series of new research projects that are being undertaken at the center to develop applications and productivity tools based on the Cell/B.

Sony Group, Toshiba and IBM Renew Cell Broadband Engine(TM) Center of Competence with Georgia Tech

ATLANTA (Business Wire) -- The Georgia Tech College of Computing today announced the renewal of the Sony Corporation/Sony Computer Entertainment Inc. (Sony Group)-Toshiba-IBM Center of Competence (STI Center), based on Georgia Tech's exceptional work in multiple areas of research and evangelism for the Cell Broadband Engine(TM) (Cell/B.E.) technology. Through Georgia Tech's efforts, the STI Center has been responsible for creating and disseminating software optimized for Cell/B.E. systems, and for performing research on the design of Cell/B.E. systems, algorithms and applications. In conjunction with this renewal of the STI Center, Georgia Tech is announcing a series of new research projects that are being undertaken at the center to develop applications and productivity tools based on the Cell/B.

Sony Group, Toshiba and IBM Renew Cell Broadband Engine(TM) Center of Competence with Georgia Tech

ATLANTA--(BUSINESS WIRE)--July 9, 2008--The Georgia Tech College of Computing today announced the renewal of the Sony Corporation/Sony Computer Entertainment Inc. (Sony Group)-Toshiba-IBM Center of Competence (STI Center), based on Georgia Tech’s exceptional work in multiple areas of research and evangelism for the Cell Broadband Engine(tm) (Cell/B.E.) technology. Through Georgia Tech’s efforts, the STI Center has been responsible for creating and disseminating software optimized for Cell/B.E. systems, and for performing research on the design of Cell/B.E. systems, algorithms and applications. In conjunction with this renewal of the STI Center, Georgia Tech is announcing a series of new research projects that are being undertaken at the center to develop applications and productivity tools based on the Cell/B.

$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells

NEW BRUNSWICK, N.J. – Rutgers University has received a $3.2 million grant from the National Science Foundation (NSF) to apply engineering, physical science and mathematical disciplines to stem cell research. In funding 70 doctoral fellowships, the program can equip experts in fields such as cell and molecular biology, computational modeling and biomaterials to move stem-cell breakthroughs from the biology lab into practical and commercially viable therapies.

Stem Cell Research - New research on stem cell research from National University, Genome Center summarized

Error: You have an error in your SQL syntax; check the manual that corresponds to your MySQL server version for the right syntax to use near 'ORDER BY RAND() LIMIT 1' at line 1

STEM CELL BREAKTHROUGH CLOSES GAP BETWEEN MOUSE AND HUMAN STUDIES

Scientists have shown for the first time that embryonic stem cells are able to self-renew without the natural chemicals that scientists have so far used to maintain them and grow stem cell lines.

Stem Cell Chicken And Egg Debate Moves To Unlikely Arena: The Testes

Logic says it has to be the niche. As air and water preceded life, so the niche, that hospitable environment that shelters adult stem cells in many tissues and provides factors necessary to keep them young and vital, must have emerged before its stem cell dependents.

Twenty Disease-specific Stem Cell Lines Created

A set of new stem cell lines will make it possible for researchers to explore ten different genetic disorders—including muscular dystrophy, juvenile diabetes, and Parkinson's disease—in a variety of cell and tissue types as they develop in laboratory cultures.

Scientists replicate diseases in the lab with new stem cell lines

A set of new stem cell lines will make it possible for researchers to explore ten different genetic disorders—including muscular dystrophy, juvenile diabetes, and Parkinson's disease—in a variety of cell and tissue types as they develop in laboratory cultures.

Scientists replicate diseases in the lab with new stem cell lines

A set of new stem cell lines will make it possible for researchers to explore ten different genetic disorders—including muscular dystrophy, juvenile diabetes, and Parkinson's disease—in a variety of cell and tissue types as they develop in laboratory cultures.

Human embryonic stem cells developed from 4-cell embryo; world first may lessen ethical concerns

Barcelona, Spain: For the first time in the world scientists have succeeded in developing human embryonic stem cells (hESCs) from a single cell, or blastomere, of a 4-cell stage embryo, the 24th annual conference of the European Society of Human Reproduction and Embryology heard today (Wednesday 9 July). Dr. Hilde Van de Velde, from the Vrije Universiteit Brussel (VUB), Brussels, Belgium, said that their research meant that it might be possible in the future to produce hESC lines at an earlier stage without destroying the embryo.

Genes That Control Embryonic Stem Cell Fate Identified

Scientists have identified about two dozen genes that control embryonic stem cell fate. The genes may either prod or restrain stem cells from drifting into a kind of limbo, they suspect. The limbo lies between the embryonic stage and fully differentiated, or specialized, cells, such as bone, muscle or fat.

Search took 0.22 seconds.